The Intersection Between Genetic Engineering and Immunotherapy: Taking a BiTE out of Glioblastoma

摘要

Conventional methods for the treatment of glioblastoma multiforme (GBM) are nonspecific and are limited by the consequent damage to normal brain tissue. Such methods including, chemotherapy radiation therapy, and gross total resection, may prolong median survival time to 15 months but can be deleterious to the patient's quality of life. New treatment modalities arising from novel genetic recombination techniques and cell-mediated immunotherapy may provide a promising treatment strategy to treating patients with GBM.